Vaccination remains the most cost-effective biomedical approach to the control of infectious diseases in livestock. Vaccines based on killed pathogens or subunit antigens are safer but are often ineffective and require coadministration with adjuvants to achieve efficacy. Unfortunately, most conventional adjuvants are poorly defined, complex substances that fail to meet the stringent criteria for safety and efficacy desired in new generation vaccines. A new generation of adjuvants that work by activating innate immunity presents exciting opportunities to develop safer, more potent vaccines. In this review the authors highlight the role of innate immunity in protection against infectious disease and provide some examples of promising new adjuvants that activate innate immunity. They do not review the conventional adjuvants present in many vaccines since they have been reviewed extensively previously.
Introduction
Infectious diseases continue to be a major cause of death and economic losses in domestic animals. Today, the most cost-effective strategy for the control of infectious diseases is clearly vaccination. Indeed, vaccination has already greatly improved livestock production and reduced animal suffering. However, there are concerns regarding many of today' s vaccines with respect to their safety and efficacy, and therefore there is a need for safer and more efficacious vaccines for livestock. Furthermore, the realisation that the majority of newly emerging diseases not only affect animals but can be transmitted to humans has created an even greater need for effective vaccines for domestic animals. Vaccines based on live and killed pathogens have traditionally been used in the livestock industry, and each of these has its perceived advantages and disadvantages. Live vaccines are often more effective as they tend to stimulate vigorous immune responses, often similar to natural infection, but they can potentially revert to virulence and cause disease especially in immunocompromised hosts. Killed vaccines or their components are generally regarded as safer, but they often fail to induce protective immunity.
The realisation that certain components in killed vaccines may be harmful to the host has led to the evolution of a vaccine development approach that involves the identification of defined molecules (protective antigens) that are associated with induction of protective immunity.
With the recent and rapid progress in molecular biology, genomics, proteomics, and immunology it is now possible to identify a myriad of potential targets for vaccine development. Furthermore, combining the advances in molecular biology with those in immunology and pathogenesis, it is now possible to correlate the immune response induced by specific proteins with different levels of protection. Thus, we now know, in most cases, what components of the infectious agent are critical for preventing infection or aiding in recovery from infection as well as which immune responses are desired. Unfortunately, it is not always easy to induce the correct immune response. This is especially the case where recombinant proteins or killed vaccines are used as immunogens. These killed antigens are generally poor at inducing immune responses and, more importantly, the quality of the immune response induced may not give optimal protection. This could possibly be improved by developing novel adjuvants and formulation technologies. Conventional adjuvants used in commercially available animal vaccines have been extensively reviewed elsewhere and the reader is referred to these excellent reviews for details (10, 48) .
A detailed understanding of the requirements for immune activation has provided an explanation for why recombinant vaccines fail to be effective. These vaccines often lack the components of pathogens that trigger 'danger' signals that activate innate immunity leading to enhanced vaccine efficacy. In this regard, the search for new adjuvants has focused on molecules that activate innate immunity. We will briefly discuss innate immunity and highlight some promising new adjuvants that enhance vaccine efficacy primarily by stimulating innate immunity.
Innate immunity
The immune system has evolved two general strategies to protect the host against infectious diseases: the innate and adaptive immune responses (Table I) . Innate immunity represents a very effective first response against invading pathogens and consists of a set of conserved mechanisms to recognise and counter the constant threat of microbial infections (3, 27) . As such, innate immunity is regulated by a network of complex receptor-ligand interactions which eventually lead to the creation of a pro-inflammatory local environment and thereby set the stage for the development of adaptive immune responses. The adaptive immune system, which is relatively slow to respond, forms the second line of immune defence, a 'back-up' strategy called into action to clear any pathogens that survive or evade the innate immune responses. Indeed, in the case of a rapidly replicating pathogen, this delay affects the success of the naïve host in attacking the invading organism (45) . Therefore, the early interplay between innate and adaptive immunity is essential for effective immunity against most invading pathogens (23). By exploiting this link between innate and adaptive immunity, it is possible to develop more potent adjuvants, leading to more effective vaccine formulations.
Stimulation of innate immunity is initiated by the interaction of pathogen components with receptors present on immune cells. These pattern recognition receptors (PRR) recognise highly conserved components of pathogens called pathogen-associated molecular patterns (PAMP) (51, 53) . Pattern recognition receptors represent a large group of conserved receptor molecules including tolllike receptors (TLR), complement receptors, C-type lectins, and nucleotide-binding oligomerisation domain (NOD) receptors NOD 1 or NOD 2 (22, 32, 43) . Following recognition of pathogen PAMP, signalling through these receptors leads to activation of the nuclear factor-B, which in turn increases expression of chemical mediators including cytokines, chemokines ( Fig. 1 ) and costimulatory molecules (34) . Several of these cytokines induce epithelial cells to express antimicrobial peptides, increasing the antimicrobial capacity of the epithelial barrier (63) . In addition, expression of these molecules creates a local pro-inflammatory environment, which helps to recruit and activate phagocytic cells, activate the complement cascade, contain the invading pathogen and chemoattract the effector cells of the adaptive immune response (Fig. 1) . However, over-stimulation can also result in septic pro-inflammatory responses such as secretion of tumour necrosis factor, which in severe cases can be detrimental to the animal. 
Adjuvants
Adjuvants were first described by Ramon (41) as 'helper' substances which when added to an antigen produce stronger immune responses than can be induced by the antigen alone. Since then many different natural and synthetic substances have been evaluated, primarily by trial and error, and some have been found to have adjuvant activity.
Adjuvants can be classified into two broad categories:
Delivery systems include many conventional adjuvants such as alum, liposomes, microparticles and oil/water emulsions. The mechanisms by which these adjuvants work are not well understood, but many of them form a 'depot' at the site of injection, where the antigen is slowly released and stimulates infiltrating cells of the immune system. Furthermore, these are often poorly defined, crude substances that have been associated with severe tissue damage at the site of injection. Ironically, the efficacy of some of these adjuvants is dependent on the degree of tissue damage, i.e. a substance that causes severe tissue damage has more potent adjuvant activity. Therefore, the challenge for vaccinologists is to discover and develop adjuvants that activate protective immunity but do not cause severe tissue damage. This paradigm shift has generated great interest in the second class of adjuvants, the immunostimulatory adjuvants, which tend to stimulate immunity with minimal or no tissue damage. These adjuvants are predominantly microbial components (Table II) and as the name suggests their adjuvant activity is dependent on their ability to stimulate innate immunity. Current understanding of how the body senses infectious threats involves the use of a variety of receptors (see innate immunity, above) which sets the stage for a 'danger' signal that triggers a cascade of innate immune responses, subsequently leading to the recruitment and expansion of cells involved in the development of adaptive immunity. In addition to their traditional role in preventing infectious diseases, vaccination strategies are also being developed as therapies for other diseases, including cancer and allergies. Development of safe and effective vaccine adjuvants is critical not only for improvement of existing vaccines but also for developing novel vaccines. In the next section the authors discuss some of these new adjuvants.
CpG oligodeoxynucleotides
As early as the 1890s, a surgeon in New York observed that cancer patients injected with crude bacterial preparations had significantly longer remission periods. Subsequently, bacterial DNA was identified as the primary mediator of anti-tumour immunity in mice (50, 58 (25, 26) . Interestingly, the use of CpG ODN in combination with low levels of mineral oil enhanced the 
Host defence peptides
Cationic host defence peptides (HDP) are endogenous antibiotics found in virtually every life form. Mammalian HDP are very short peptides that can be grouped into defensins and cathelicidins. Typically, HDP are amphipathic positively charged molecules (20, 39) .
Host defence peptides are fundamental components of the innate immune response. Their wide spectrum of functions includes direct antimicrobial activities, immunostimulatory functions of both innate and acquired immunity, and involvement in wound healing, cell trafficking and vascular growth (9, 12, 36) . While the antimicrobial activities of HDP have been known for a long time, recent evidence suggests that at physiological concentrations mammalian HDP have a number of immunomodulatory functions, including recruitment of immature DC and T-cells, glucocorticoid production, macrophage phagocytosis, mast cell degranulation, complement activation, and IL-8 production by epithelial cells (59, 61, 62) . Other HDP have been shown to upregulate gene expression in epithelial cells and monocytes, and to neutralise pro-inflammatory cytokine induction and lethality in response to LPS/endotoxin (2, 7, 9, 16, 19, 20, 29, 36, 37, 46, 47) .
Evidence for the ability of HDP to enhance adaptive immunity (indicative of adjuvant activity) is based on various observations. For example, human neutrophil peptides (HNP) 1 to 3, human beta-defensins 1 and 2, and murine beta-defensins (mBD) have been described to be chemoattractive for immature DC and lymphocytes (4, 60) , and monocytes and macrophages (21) . Recognition by immature DC occurs through chemokine receptor 6 (4) and other not yet identified receptors (60) . Furthermore, in addition to chemoattraction of immature DC, HDP have also been demonstrated to attract mature DC (4, 6, 16) . The immunoenhancing activity of HDP has been demonstrated in several studies. For example, ovalbumin-specific immune responses were enhanced in mice when HNP 1-3 were co-administered intranasally to C57/Bl mice (30). This observation was further supported by other investigators (49) who demonstrated that intraperitoneal injection of HNP 1-3 together with keyhole limpet haemocyanin (KLH) and B-cell lymphoma idiotype antigen into mice enhanced the resistance of immunised mice to subsequent tumour challenge. Brogden et al. (11) also confirmed the immunoenhancing activity of various defensins. More evidence for the immunoenhancing activity of HDP is derived from studies using DNA vaccines. When mBD2 and mBD3 were fused with B-cell lymphoma epitope sFv38, strong immune responses and stronger anti-tumour immunity were observed in immunised mice (4, 6) . The same researchers also demonstrated that human immunodeficiency virus-1 glycoprotein 120 (HIV gp120) specific mucosal, systemic, and cytotoxic lymphocyte (CTL) immune responses could be achieved after immunisation with a fusion DNA vaccine encoding the murine ␤-defensin 2 and the HIV gp120 gene (5) . Thus, these examples provide evidence that HDP can be used as adjuvants to enhance vaccine-specific immunity.
To co-formulate HDPs into novel vaccines several issues need to be addressed, including reduction of the cost of producing the peptide, co-formulation and possible interaction with the antigen, and the stability and safety of the vaccine formulation. Recent research has already demonstrated that short peptide derivatives of only 7 to 12 amino acids, which include only specific motifs for certain functions, can behave very similarly to the parental HDP (8) . These derivatives are much cheaper to produce and potentially have less interaction with other vaccine components. More research is required to better understand the peptide motifs that are responsible for immunomodulatory and antimicrobial functions. In addition, although a large variety of HDP has been described in domestic animals (11) very little information is currently available about the immunomodulatory functions of these peptides. Thus, future research needs to address the immunoenhancing activities of these HDP in their respective host species, analyse their potential crossspecies activity and investigate the prophylactic potential for preventing infectious disease in domestic animals. However, preliminary results provide a degree of hope that these molecules will be able to improve vaccine responses with minimal adverse reactions. 
Ribonucleic acid oligonucleotides and imidazoquinolines

Polyphosphazenes
Polyphosphazenes are synthetic, water-soluble and biodegradable polymers that are inexpensive to produce. One of the most interesting properties of polyphosphazenes is that they are stable at room temperature and can be stored on the bench for several months without loss of activity, eliminating the need for refrigeration. The prototype member of this class of polymers is poly[di(sodium carboxylatophenoxy) phosphazene] (PCPP) which has previously been shown to have adjuvant activity with a variety of viral and bacterial antigens in mice (33, 40, 57) . Despite the compelling evidence for adjuvant activity of these polymers in mice, they have not been tested in large animals. In this regard, the authors have shown that PCPP is also a potent adjuvant in sheep when used at only double the dose used in mice (Mutwiri et al., unpublished data) . A new polyphosphazene polyelectrolyte, poly[di(sodium carboxylatoethylphenoxy]phosphazene) (PCEP) seems to have even more potent adjuvant activity (38) . Evidence from numerous studies in mice demonstrates that PCEP is a potent enhancer of antigen-specific immune responses, and its adjuvant activity is far superior to that of PCPP and the conventional adjuvant alum (38) . PCEP not only enhanced the magnitude but modulated the quality of immune responses, resulting in more balanced immunity (38) . Even more interesting was the observation that the combination of PCEP with CpG showed strong synergy, resulting in dramatic increase in immune responses. The authors hypothesise that because PCEP induces immune responses that have similarities with those stimulated by CpG DNA, PCEP achieves its adjuvant effects by activating innate immunity. Indeed, they have obtained evidence that PCEP activates immune cells to secrete cytokines that have been associated with the development of Th1 type immune responses (Mutwiri et al., manuscript submitted) . Thus, activation of innate immunity may be at least one of the mechanisms by which PCEP mediates its potent adjuvant activity. PCEP has not yet been tested in livestock. Given its success in mice, studies in large animals are certainly warranted.
Conclusion
Looking to the future, many new generation vaccines will consist of purified antigens and well-defined adjuvants, and these vaccines will be expected to meet more stringent safety and efficacy requirements. A few examples of directions in which the field of adjuvant development may be headed in the future have been provided here. The authors anticipate that, in future, adjuvants will be used as high precision tools to activate the desired immune responses. In this regard, the selection of adjuvants will be much more focused on stimulating specific immune responses, and not just enhancing antibody responses. Thus, there will be more emphasis on the quality of the immune response with fewer adverse reactions. The use of stimulators of innate immunity such as CpG or other selective modulators of the innate immune response, combined with better formulations, should dramatically improve vaccine efficacy and reduce economic losses to the livestock industry. Furthermore, these more defined vaccine formulations, together with the understanding of their mode of action, should provide the regulatory agencies with a greater level of confidence in the new vaccines. Those vaccines currently being developed will be safer for use in livestock, which is particularly important for food-producing animals that will eventually be consumed by humans. Resumen La vacunación sigue siendo el procedimiento biomédico más rentable para luchar contra las enfermedades infecciosas del ganado. Las vacunas basadas en patógenos muertos o subunidades antigénicas presentan menos riesgos, pero con frecuencia es preciso administrarlas con adyuvantes para que sean eficaces. Lamentablemente, la mayoría de los adyuvantes convencionales son sustancias complejas, mal definidas, que no satisfacen los criterios estrictos en materia de inocuidad y eficacia que las vacunas de nueva generación deben cumplir. La nueva generación de adyuvantes que potencia la inmunidad innata representa una oportunidad muy interesante para obtener vacunas más seguras y potentes. En este artículo los autores destacan el papel de la inmunidad innata en la protección contra enfermedades infecciosas y presentan algunos ejemplos de nuevos adyuvantes prometedores que la potencian. No examinan los adyuvantes convencionales utilizados en muchas vacunas puesto que ya fueron analizados exhaustivamente en el pasado.
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